How To Position Your Program To Investors: Leveraging FDA Feedback To Communicate Risk And Boost Confidence

When pitching to investors, a sponsor is not just selling them on the product; it is also selling them on its own ability to develop that product. Investors want to know the risks involved with the program, but they are also evaluating the sponsor as a risk factor of its own.
Previously on this blog, we have described how sponsors can set themselves up for an effective Pre-IND meeting with the FDA and what a truly successful meeting looks like. Many sponsors use the completion of that initial FDA meeting as a springboard for external capital raise, as the outcome of the Pre-IND meeting can be a useful fundraising tool. The trick is figuring out how to translate the FDA’s feedback into a compelling investor pitch.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.